Ranbaxy Laboratories Ltd.
Ranbaxy Laboratories Ltd., a prominent player in the pharmaceutical industry, is headquartered in India. Founded in 1961, the company has established itself as a leader in the development and manufacturing of generic and branded medications, with a strong presence in various global markets, including North America, Europe, and Asia. Specialising in a diverse range of therapeutic areas, Ranbaxy offers a unique portfolio of products, including antibiotics, cardiovascular medications, and anti-diabetics. The company is recognised for its commitment to quality and innovation, having achieved significant milestones such as the introduction of several first-to-file generic drugs. With a robust market position, Ranbaxy has garnered numerous accolades for its contributions to healthcare, making it a trusted name in the pharmaceutical sector. Its dedication to research and development continues to drive its success in delivering affordable healthcare solutions worldwide.
DitchCarbon Score
How does Ranbaxy Laboratories Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ranbaxy Laboratories Ltd.'s score of 58 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ranbaxy Laboratories Ltd., headquartered in India, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Sun Pharmaceutical Industries Limited, which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges from Ranbaxy Laboratories Ltd. However, emissions data and performance metrics may be inherited from its parent company, Sun Pharmaceutical Industries Limited. This cascading of data suggests that any climate initiatives or targets would align with those set by Sun Pharmaceutical. In the broader context, the pharmaceutical industry is increasingly focusing on sustainability and reducing carbon footprints. Companies are encouraged to adopt science-based targets and engage in initiatives that promote environmental responsibility. While specific commitments from Ranbaxy are not detailed, the industry trend indicates a growing emphasis on climate action and emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ranbaxy Laboratories Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
